|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Chromosomal Microarray, Hematologic Malignancy, ClariSure® Oligo-SNP
Test Code90961
CPT Codes
81277
Preferred Specimen
3 mL bone marrow collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL bone marrow • 3 mL peripheral blood
Other Acceptable Specimens
Bone marrow collected in: Sodium heparin (royal blue-top), sodium heparin lead-free (tan-top), EDTA (lavender-top) tube, acid citrate dextrose ACD-A or B (yellow-top) tube • 5 mL peripheral blood collected in: Sodium heparin (green-top), sodium heparin (royal blue-top), sodium heparin lead-free (tan-top), EDTA (lavender-top), acid citrate dextrose ACD-A or B (yellow-top) tube • 5x5 mm fresh Tumor biopsy collected in a transport media
Instructions
Solid tumor specimen requirement: Submit a tumor biopsy in a transport medium (available upon request). Alongside send the pathology report with the diagnosis/clinical indication.
See genetics specimen collection section for detailed specimen instructions.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
See genetics specimen collection section for detailed specimen instructions.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: See Instructions
Refrigerated: See Instructions
Frozen: See Instructions
Refrigerated: See Instructions
Frozen: See Instructions
Methodology
Oligo-SNP Array
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 12 days
Reference Range
See Laboratory Report
Clinical Significance
To integrate the microarray in the investigation of neoplasms to assess genomic alterations and overall genomic complexity of the abnormal clone. To be used in conjunction with other established clinical laboratory tests for the malignancy in question.